Sintilimab plus chemo vs. chemo alone for stomach cancer after surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stomach or gastroesophageal junction adenocarcinoma.
- Your cancer stage is IIIA, IIIB, or IIIC after surgery and it has a mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) feature.
- You had a D2 or more extensive surgery and all visible cancer was removed (R0 resection).
- You are at least 18 years old and able to swallow tablets.
- Your overall health is good (ECOG 0-1) and your organ function meets specific lab criteria.
- You have not had previous immunotherapy (anti-PD-1/PD-L1) or certain other treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a new combination of IBI343, sintilimab, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. It's for those whose tumors are CLDN18.2-positive and not HER2-positive.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
This trial tests whether adding an immunotherapy drug called sintilimab to chemotherapy and radiation before surgery can help shrink tumors and improve outcomes for people with gastroesophageal junction cancer. It is designed for patients who have not had previous treatment for this cancer.
Hear when a new Gastric Cancer or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.